Related Experiment Video
Updated: Jun 17, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Epidemiology of thrombotic risk factors: the difficulty in using clinical trials to develop a risk assessment model
Silvy Laporte1, Patrick Mismetti
1University Jean Monnet Saint-Etienne, EA3065, Saint-Etienne, France. silvy.laporte@chu-st-etienne.fr
Abstract:
There is a paucity of data assessing the risks and prevention of venous thromboembolism in critical care settings. Consequently, it is difficult to estimate the risk of venous thromboembolism for a typical patient, on an individual basis, and this difficulty leads to underuse of thromboprophylaxis, especially in intensive care unit patients. Thrombosis is a multifactorial disease and patients may present multiple risk factors simultaneously. The problem in quantifying risk factors is to combine these risk factors even when they are not detected in the same multivariate analysis. A model for predicting the risk of venous thromboembolism in hospitalized medical patients has yet to be developed and validated. Meanwhile, other approaches have been proposed to replace the ideal study utilizing a large prospective cohort of hospitalized medical patients. In this context, several scoring systems based on risk assessment models have been proposed, some including the use of computerized electronic prompts, to help physicians prescribe appropriate prophylaxis. This article reviews evidence on the risk of venous thromboembolism associated with different medical conditions and risk factors, and presents a tentative risk-assessment model for risk stratification in hospitalized medical patients.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis I: Introduction
